Marshall Wace’s Strongbridge Biopharma plc. SBBP Stock Holding History

Marshall Wace’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,529	Closed	-$23K	–	2017
2019 Q1	$23K	Buy	+4,529	New	+$22.3K	﹤0.01%	1623
2018 Q4	–	Sell	-265,934	Closed	-$1.29M	–	1897
2018 Q3	$1.29M	Buy	+265,934	New	+$1.36M	0.01%	761
2018 Q2	–	Sell	-37,500	Closed	-$332K	–	893
2018 Q1	$332K	Buy	+37,500	New	+$281K	0.01%	456

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Marshall Wace's SBBP Position: Q2 2019 in Review

Marshall Wace sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2019, closing a stake of 4,529 shares — an estimated $23K sold.

Marshall Wace first reported a position in SBBP in Q1 2018 and held it in 3 quarters. The position peaked at $1.29M in Q3 2018. 58 funds tracked by Wall St. Rank hold SBBP as of Q2 2019.

Marshall Wace reported no remaining Strongbridge Biopharma plc. position as of Q2 2019 after selling out during the quarter.
Marshall Wace sold 4,529 Strongbridge Biopharma plc. shares in Q2 2019, an estimated $23K.
Marshall Wace first reported a position in Strongbridge Biopharma plc. in Q1 2018 and held it in 3 quarters.
Marshall Wace's Strongbridge Biopharma plc. position peaked at $1.29M in Q3 2018.
58 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2019.

Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.